ATG-022

Phase 3Small molecule

ATG-022 is one of 32 small molecule programs targeting Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting

Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting

Advanced/metastatic Solid TumorsRecruiting

Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPreclinical

Recruiting

Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3

Not yet recruiting

Advanced/metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

50 competitors in Advanced/metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

8 2

Fludara

Sanofi

Phase 2

2 3

Zytiga

Johnson & Johnson

Phase 2

1 4

Tagrisso

AstraZeneca

Phase 2

1 5

Xtandi

Astellas

Phase 2

1 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 7

Herceptin

OOrganon and Co

Phase 2

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

1 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 10

BNT327

BioNTech

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07327229

Q4 2029

Phase 3Not yet recruiting

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07795346

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Recruiting·AAntengene Biologics Limited·Phase 1·NCT05718895·156 enrolled

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ATG-022 Compared With Investigator's Choice of Treatment in Subjects With Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·AAntengene Biologics Limited·Phase 3·NCT07795346·380 enrolled

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAntengene Biologics Limited·Preclinical·NCT07327229·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ATG-022. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATG-022 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATG-022. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Antengene Biologics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAntengene Biologics Limited

ATG-022

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News